StoxDr. Reddy's Laboratories vs Aurobindo Pharma: share price & financials comparison
NSE: DRREDDY vs AUROPHARMA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Reddy's Laboratories vs Aurobindo Pharma at a glance
Dr. Reddy's Laboratories (DRREDDY) has a market capitalisation of ₹1,14,646 Cr, against ₹1,03,572 Cr for Aurobindo Pharma (AUROPHARMA). Over the past year Aurobindo Pharma has returned +61.9%, compared with +9.8% for Dr. Reddy's Laboratories. On valuation, Aurobindo Pharma trades at a lower P/E of 26.0 versus 40.9. Aurobindo Pharma earns a higher return on equity (10.1% vs 7.2%). Dr. Reddy's Laboratories comes out ahead on size and financial health. Aurobindo Pharma comes out ahead on valuation, profitability, growth, momentum and technicals. Across the scored metrics below, Dr. Reddy's Laboratories leads on 5 and Aurobindo Pharma on 13. On StoxGud's 10-point checklist, Dr. Reddy's Laboratories scores 5/10 and Aurobindo Pharma scores 9/10.
| Metric | Dr. Reddy's Laboratories | Aurobindo Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,14,646 Cr | ₹1,03,572 Cr |
| Revenue (latest FY) | ₹33,700 Cr | ₹33,653 Cr |
| Net profit (latest FY) | ₹4,196 Cr | ₹3,505 Cr |
| Valuation | ||
| P/E | 40.9 | 26.0 |
| P/B | 2.95 | 2.63 |
| Dividend yield | 0.58% | 0.22% |
| Profitability | ||
| Return on equity | 7.2% | 10.1% |
| Net profit margin | 8.5% | 10.8% |
| Operating margin | 14.7% | 20.5% |
| Growth | ||
| Revenue growth (YoY) | -1.5% | +23.9% |
| Net profit growth (YoY) | -31.3% | +32.7% |
| Revenue CAGR (multi-year) | +12.1% | +6.3% |
| Financial health | ||
| Debt to equity | 0.15 | 0.21 |
| Momentum | ||
| 1-month return | +14.1% | +7.0% |
| 1-year return | +9.8% | +61.9% |
| 3-year CAGR | +8.7% | +27.2% |
| 5-year CAGR | +7.5% | +21.8% |
| 10-year CAGR | +8.3% | +8.9% |
| Distance from 52W high | -0.2% | +0.0% |
| Technicals | ||
| RSI (14) | 84 | 67 |
| Price vs 200-day avg | +9.9% | +22.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Reddy's Laboratories | Aurobindo Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Reddy's Laboratories or Aurobindo Pharma?
Dr. Reddy's Laboratories has a market cap of ₹1,14,646 Cr and Aurobindo Pharma has a market cap of ₹1,03,572 Cr as of 06 Nov 2026.
Which has a lower P/E, Dr. Reddy's Laboratories or Aurobindo Pharma?
Aurobindo Pharma has the lower P/E: Dr. Reddy's Laboratories trades at 40.9 and Aurobindo Pharma at 26.0.
Which gave better returns in the last year, Dr. Reddy's Laboratories or Aurobindo Pharma?
Aurobindo Pharma did better: Dr. Reddy's Laboratories returned +9.8% and Aurobindo Pharma returned +61.9% over one year.
Is Dr. Reddy's Laboratories or Aurobindo Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Dr. Reddy's Laboratories scores 5/10 and Aurobindo Pharma scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.